Hemay022

Hemay022 is an investigational therapeutic candidate developed by Tianjin Hemay Biotech, currently in Phase 1 clinical trials for the treatment of advanced breast cancer. According to company pipeline data, the drug is designed as either a bispecific antibody or an antibody-drug conjugate (ADC) that simultaneously targets the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2). This dual-targeting approach is intended to inhibit multiple signaling pathways involved in tumor growth and survival, such as PI3K/Akt and MAPK, while potentially delivering a cytotoxic payload directly to cancer cells. While some clinical literature identifies Hemay022 as sacibertinib, a small-molecule tyrosine kinase inhibitor (TKI) in Phase 3 development, the company's internal pipeline also categorizes a Phase 1 project under this designation with the bispecific/ADC modality.